|
Excluding items, Dublin-based Allergan earned $3.35 per share,
helped by sales of its newer medicines and key products,
including Botox.
Analysts on average expected earnings of $3.30 per share,
according to Thomson Reuters I/B/E/S.
Allergan in February agreed to buy Zeltiq, a device that is
designed to freeze fat away, adding to its line-up of aesthetic
products.
The company raised its net revenue forecast to $15.8 billion-$16
billion, from $15.5 billion-$15.8 billion.
Net loss attributable to ordinary shareholders was $2.63
billion, or $7.86 per share, in the first quarter ended March
31, compared with a profit of $186.1 million, or 47 cents per
share, a year earlier.
The company reported a first-quarter loss primarily due to
amortization, research and development related charges and
in-process research and development impairments.
Amortization expenses from continuing operations was $1.74
billion, compared with $1.59 billion in the year-ago quarter.
Net revenue for the acquisitive company rose to $3.57 billion
from $3.40 billion.
(Reporting by Natalie Grover in Bengaluru; Editing by Martina
D'Couto)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
